一二三四区视频,亚洲少妇熟女色,日本久热无码视频网,欧美国产日韩大尺度,亚洲a视频,久久少妇一区二区,日韩999无码视频,刺激久久久久久久,啊啊啊啊不要啊在线

ChemicalBook >> journal list >> Drugs >>article
Drugs

Drugs

IF: 13
Download PDF

Letermovir: First Global Approval.

Published:1 January 2018 DOI: 10.1007/s40265-017-0860-8 PMID: 29288370
Esther S Kim

Abstract

Letermovir (Prevymis?) is an orally or intravenously administered cytomegalovirus (CMV) DNA terminase complex inhibitor being developed by Merck & Co., Inc., under a global license from AiCuris Anti-infective Cures GmbH. Letermovir has been approved in Canada and the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic haematopoietic stem cell transplant (HSCT). In addition, letermovir has received a positive opinion from the European Medicines Agency's Committee for Medicinal Products for Human Use, and is under review in several countries, including Japan. This article summarizes the milestones in the development of letermovir leading to its first global approval in Canada as well as the USA for the prophylaxis of CMV infection and disease in adult CMV-seropositive recipients of an allogeneic HSCT.

Substances (2)

Related products
Procduct Name CAS Molecular Formula Supplier Price
Letermovir 917389-32-3 C29H28F4N4O4 271 suppliers $15.00-$4741.00
Letermovir 710312-77-9 C34H47N11O9S2 8 suppliers Inquiry

Similar articles

IF:4.1

Capmatinib: First Approval.

ACS Chemical Neuroscience Sohita Dhillon,etc Published: 1 July 2020
IF:3.4

Sodium Thiosulfate: Pediatric First Approval.

Pediatric Drugs Sohita Dhillon,etc Published: 1 March 2023
IF:3.4

Letermovir for cytomegalovirus prophylaxis

Australian Prescriber Published: 24 April 2019
绍兴市| 巫山县| 姜堰市| 怀柔区| 花垣县| 汝阳县| 江达县| 大足县| 崇信县| 花垣县| 大英县| 嘉兴市| 拉孜县| 鹰潭市| 大洼县| 广昌县| 德钦县| 买车| 建水县| 福安市| 芦溪县| 石城县| 新宾| 开封市| 达孜县| 台州市| 斗六市| 香港| 读书| 金堂县| 济南市| 汕尾市| 含山县| 沙洋县| 崇明县| 霸州市| 新巴尔虎左旗| 石门县| 江川县| 中江县| 临潭县|